BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25655637)

  • 41. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnosis and staging of cardiac masses: additional value of CMR with
    Mikail N; Males L; Hyafil F; Benali K; Deschamps L; Brochet E; Ehmer C; Driss AB; Saker L; Rossi A; Alkhoder S; Raffoul R; Rouzet F; Ou P
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2232-2241. PubMed ID: 35247063
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas.
    Giovanella L; Ceriani L; De Palma D; Suriano S; Castellani M; Verburg FA
    Head Neck; 2012 May; 34(5):626-31. PubMed ID: 21850699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection.
    Lee YG; Han SW; Oh DY; Chie EK; Jang JY; Im SA; Kim TY; Kim SW; Ha SW; Bang YJ
    BMC Cancer; 2011 May; 11():188. PubMed ID: 21599995
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Whole-body 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma.
    Yen RF; Hong RL; Tzen KY; Pan MH; Chen TH
    J Nucl Med; 2005 May; 46(5):770-4. PubMed ID: 15872349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE.
    Song HJ; Cheng JY; Hu SL; Zhang GY; Fu Y; Zhang YJ
    Clin Radiol; 2015 Feb; 70(2):128-37. PubMed ID: 25459673
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
    Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
    Panagiotidis E; Datseris IE; Rondogianni P; Vlontzou E; Skilakaki M; Exarhos D; Bamias A
    Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
    [TBL] [Abstract][Full Text] [Related]  

  • 51. To Enhance or Not to Enhance? The Role of Contrast Medium
    Massollo M; Fiz F; Bottoni G; Ugolini M; Paparo F; Puppo C; Provinciali N; Iacozzi M; Altrinetti V; Cistaro A; Cabria M; DeCensi A; Treglia G; Piccardo A
    Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34206116
    [No Abstract]   [Full Text] [Related]  

  • 52. Supraclavicular lymph nodes detected by 18F-FDG PET/CT in cancer patients: assessment with 18F-FDG PET/CT and sonography.
    Lee JH; Kim J; Moon HJ; Cho A; Yun M; Lee JD; Kang WJ
    AJR Am J Roentgenol; 2012 Jan; 198(1):187-93. PubMed ID: 22194496
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Comparison of Computed Tomography Perfusion, Contrast-Enhanced Computed Tomography and Positron-Emission Tomography/Computed Tomography for the Detection of Primary Esophageal Carcinoma.
    Genc B; Kantarci M; Sade R; Orsal E; Ogul H; Okur A; Aydin Y; Karaca L; Eroğlu A
    Med Princ Pract; 2016; 25(3):254-9. PubMed ID: 26784024
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Performance of FDG PET/ceCT in the evaluation of patients with lung cancer.
    Nanni C; Rossetti V; Zompatori M; Ambrosini V; Montesi V; Mascherini D; Pettinato C; Marzola MC; Colletti PM; Rubello D; Fanti S
    Biomed Pharmacother; 2014 Mar; 68(2):219-23. PubMed ID: 24486108
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cross-modality PET/CT and contrast-enhanced CT imaging for pancreatic cancer.
    Zhang J; Zuo CJ; Jia NY; Wang JH; Hu SP; Yu ZF; Zheng Y; Zhang AY; Feng XY
    World J Gastroenterol; 2015 Mar; 21(10):2988-96. PubMed ID: 25780297
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging.
    Sharma P; Kumar R; Singh H; Jeph S; Sharma JB; Jain SK; Sharma DN; Bal C; Malhotra A
    Nucl Med Commun; 2012 Feb; 33(2):185-90. PubMed ID: 22107993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
    Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
    Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Role of 18F-FDG PET/CT in comparison with CECT for whole-body assessment of patients with esophageal cancer.].
    Altini C; Niccoli Asabella A; Lavelli V; Bianco G; Ungaro A; Pisani A; Merenda N; Ferrari C; Rubini G
    Recenti Prog Med; 2019 Mar; 110(3):144-150. PubMed ID: 30968855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FDG-PET/CT as a post-treatment restaging tool in urothelial carcinoma: Comparison with contrast-enhanced CT.
    Kitajima K; Yamamoto S; Fukushima K; Yamakado K; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Hirota S
    Eur J Radiol; 2016 Mar; 85(3):593-8. PubMed ID: 26860672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.